Overview

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Status:
Recruiting
Trial end date:
2035-01-01
Target enrollment:
Participant gender:
Summary
Given the compelling evidence supporting a protective effect of statins on breast cancer recurrence, calls for prospective clinical trials have been expressed. In this trial - the MASTER trial - we hypothesize that the addition of statin treatment to the current breast cancer treatment will improve the prognosis of women with early breast cancer. This trial is designed as follows: a randomized, multicenter, double-blind, placebo-controlled comparison of standard (neo)adjuvant therapy plus placebo versus standard (neo)adjuvant therapy plus atorvastatin in patients with early breast cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Aarhus University Hospital
Collaborators:
Aalborg University Hospital
Bornholms Hospital
Herning Hospital
Hospital of Southern Jutland
Naestved Hospital
Nordsjaellands Hospital
Odense University Hospital
Rigshospitalet, Denmark
Sygehus Sønderjylland
University of Copenhagen
Vejle Hospital
Treatments:
Atorvastatin